Skip to main content
Evidence Snapshot

Solute carrier family 22 member 12

CHEMBL6120 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6120
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Solute carrier family 22 member 12 as ChEMBL target CHEMBL6120, mapped to UniProt Q96S37. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Solute carrier family 22 member 12
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6120
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96S37
Solute carrier family 22 member 12
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Solute carrier family 22 member 12 matters

As of 2026-09-13

Solute carrier family 22 member 12 is reviewed as Solute carrier family 22 member 12 (UniProt Q96S37); Solute carrier family 22 member 12 shows approved-linked disease relevance led by gout. 5 more disease programs remain visible in the same review block.; 7 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 1227 compounds, and 97 assays, with lead potency reaching pChEMBL 9.0.

Disease context
gout

Solute carrier family 22 member 12 shows approved-linked disease relevance led by gout. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ARHALOFENATE, BENZBROMARONE, DOTINURAD.

Start review with gout because it currently carries approved-linked support. Linked drugs include ARHALOFENATE, BENZBROMARONE, DOTINURAD, LESINURAD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 7 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 1227 compounds, and 97 assays for this target. The dominant activity type is IC50. CHEMBL3688197 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL3688197 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Solute carrier family 22 member 12 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96S37, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why gout is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1227
Total Compounds
97
Total Assays
6
Approved Drugs
IC50: 1191.0, KI: 3.0, EC50: 143.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3688197
 9.0 IC50 —
No preferred name
CHEMBL4087516
 8.7 IC50 —
No preferred name
CHEMBL3688190
 8.7 IC50 —
No preferred name
CHEMBL3688192
 8.5 IC50 —
No preferred name
CHEMBL5414132
 8.4 IC50 —

Approved Drugs

Structure Compound First Approval
BENZBROMARONE
CHEMBL388590
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:57Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL6120